| 0.2425 -0.017 (-6.69%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.84  |
1-year : | 1.21 |
| Resists | First : | 0.72 |
Second : | 1.03 |
| Pivot price | 0.29 |
|||
| Supports | First : | 0.22 | Second : | 0.18 |
| MAs | MA(5) : | 0.25  |
MA(20) : | 0.32 |
| MA(100) : | 1.07 |
MA(250) : | 1.16 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 17.5 |
D(3) : | 16.8 |
| RSI | RSI(14): 21.9 |
|||
| 52-week | High : | 2.78 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NDRA ] has closed above bottom band by 26.5%. Bollinger Bands are 64.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.26 - 0.26 | 0.26 - 0.26 |
| Low: | 0.23 - 0.23 | 0.23 - 0.23 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Thu, 28 Mar 2024
ENDRA Life Sciences Inc. (NDRA) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 26 Mar 2024
ENDRA Life Sciences Inc expected to post a loss of 36 cents a share - Earnings Preview - XM
Tue, 14 Nov 2023
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update - Barron's
Tue, 22 Aug 2023
How Will the Market React to ENDRA Life Sciences Inc (NDRA) Stock Getting a Bearish Rating - InvestorsObserver
Fri, 28 Apr 2023
Why Is ENDRA Life Sciences (NDRA) Stock Down 16% Today? - InvestorPlace
Thu, 18 Jun 2020
Can You Name the $15 Million Stock with the Keys to a $35 Billion Market - Small Cap Exclusive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 11 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 31 (K) |
| Shares Short P.Month | 55 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -82.1 % |
| Return on Equity (ttm) | -156.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | 0 |
| Price to Book value | 0.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|